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Ignavine: a novel allosteric 
modulator of the μ opioid receptor
Katsuya Ohbuchi1,2, Chika Miyagi1,2, Yasuyuki Suzuki1, Yasuharu Mizuhara1, Keita Mizuno1, 
Yuji Omiya1, Masahiro Yamamoto1, Eiji Warabi3, Yuka Sudo2,4, Akinobu Yokoyama2,4, 
Kanako Miyano2, Takatsugu Hirokawa5,6 & Yasuhito Uezono2,7
Processed Aconiti tuber (PAT) is used to treat pain associated with various disorders. Although it has 
been demonstrated that the κ opioid receptor (KOR) signaling pathway is a mediator of the analgesic 
effect of PAT, active components affecting opioid signaling have not yet been identified. In this study, 
we explored candidate components of PAT by pharmacokinetic analysis and identified ignavine, which 
is a different structure from aconitine alkaloids. A receptor binding assay of opioid receptors showed 
that ignavine specifically binds the μ opioid receptor (MOR), not the KOR. Receptor internalization 
assay in MOR-expressing cell lines revealed that ignavine augmented the responses produced by 
D-Ala(2)-N-Me-Phe(4)-Gly-ol(5)-enkephalin (DAMGO), a representative MOR agonist, at a low 
concentration and inhibited it at a higher concentration. Ignavine also exerted positive modulatory 
activity for DAMGO, endomorphin-1 and morphine in cAMP assay. Additionally, ignavine alone showed 
an analgesic effect in vivo. In silico simulation analysis suggested that ignavine would induce a unique 
structural change distinguished from those induced by a representative MOR agonist and antagonist. 
These data collectively suggest the possibility that ignavine could be a novel allosteric modulator of the 
MOR. The present results may open the way for the development of a novel pain management strategy.
The tuber of the species Aconitum is a crude drug that has been utilized from ancient times. Since the Aconiti 
tuber has toxic ingredients, attempts to reduce its toxicity have been made by heating. The processed Aconiti tuber 
(PAT) is used in Japan to treat pain associated with various disorders as an important component of Japanese 
traditional medicines (Kampo) such as Goshajinkigan (GJG) and Keishikajutsubuto. It has been reported that 
PAT exhibits pharmacological effects such as analgesia1–4, peripheral vasodilation5,6, anti-inflammatory7 and 
anti-pollakiuria8 effects in rodent models. In the clinic, the analgesic effect of Keishikajutsubuto was enhanced by 
the addition of PAT9.
Regarding the analgesic effect, PAT showed beneficial effects in repeatedly cold-stressed mice3 and in a rat 
model of chronic constriction injury (CCI)2. It has been reported that the analgesic effects of PAT can be blocked 
by anti-dynorphin antibody10 and by nor-binaltorphimine (nor-BNI)2, a specific antagonist of the κ opioid recep-
tor (KOR). In addition, PAT bas been shown to ameliorate morphine tolerance and this effect was also blocked 
by nor-BNI11,12. These results suggested that these pharmacological effects must be mediated by direct or indirect 
activation of the KOR.
On the other hand, no active ingredients which affect the dynorphin-KOR system have been identified. 
Although it is well known that aconitine alkaloids in PAT such as mesaconitine13, aconitine14 and benzoylmesa-
conine15 have analgesic activity, it remains unclear whether these aconitine alkaloids act on the opioid systems. 
It has been noted that the content of diester-type alkaloids such as mesaconitine and aconitine are converted 
to monoester alkaloids such as benzoylmesaconine and benzoylhypaconine by heating the Aconiti tuber. The 
analgesic effect of PAT was shown to be comparable to that of the unprocessed Aconiti tuber in a mouse model 
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of repeated cold stress1. Additionally, the analgesic activity of benzoylmesaconine, the main component of PAT, 
would not be enough to fully account for the analgesic effect of PAT15. Therefore it is likely that there are other 
unknown ingredients contributing to the analgesic effect.
In the present study, candidate ingredients were identified by performing a pharmacokinetic study of 
GJG, which was found to be composed of ten crude drugs including PAT and to have analgesic activity16,17 
(Supplementary Figure S1). Ignavine was also detected in the plasma of GJG-treated rats. Characterization in vitro, 
in vivo and in silico revealed that ignavine has a unique character as a μ opioid receptor (MOR) modulator with 
analgesic activity.
Results
Pharmacokinetic study of the PAT-containing traditional medicine, GJG. A pharmacokinetic 
study of GJG was performed to identify the bioavailable molecules in PAT. GJG (1 g/kg) was orally administered 
to rats and blood samples were collected 1 h after administration. Then, representative components of PAT in the 
collected blood samples were measured by LC/MS/MS. As shown in Fig. 1A, higher concentrations of ignavine 
(Fig. 1B) and of benzoylmesaconine were detected among the measured ingredients. Therefore, we further inves-
tigated whether ignavine and benzoylmesaconine affect the opioid system.
Receptor binding assay for opioid receptors. First, the receptor binding assay was performed using 
membrane fractions prepared from human MOR-, δ opioid receptor (DOR)-, KOR-, and nociception receptor 
(NOP)-expressing cell lines and from rat brain for evaluation of non-specific binding. The % inhibition at a 
concentration of 10 μ M is shown in Fig. 2A. Neither ignavine nor benzoylmesaconine inhibited the binding of 
radio-labeled ligand ([3H]-diprenorphine) to KOR, which was thought to be involved in the analgesic effect of 
PAT. On the other hand, unexpectedly, ignavine almost completely inhibited [3H]-diprenorphine binding to an 
MOR-expressing membrane. Ignavine also inhibited its binding in the membrane fraction from rat brain. Dose 
titration analysis of ignavine showed that its IC50 value was 2.0 μ M (Fig. 2B).
Receptor internalization assay of ignavine. To clarify whether ignavine was an agonist or antago-
nist of MOR, a receptor internalization assay was performed using GFP-tagged MOR-expressing HEK-293 
cells. Photomicrographs of representative cells are shown in Fig. 3 and all field views of cells treated with 1 μ 
M D-Ala(2)-N-Me-Phe(4)-Gly-ol(5)-enkephalin (DAMGO) and 1 μ M DAMGO with 1 μ M ignavine are shown 
in Supplementary Figure S2. As shown in Fig. 3, fluorescence was mainly detected on the surface of the cell 
membrane (0 min in Fig. 3). Twenty minutes after treatment with 1 μ M DAMGO, vesicles were observed in the 
intracellular space, indicating receptor internalization (Fig. 3, shown by red arrow-head). Treatment with 10 μ M 
ignavine alone did not affect receptor internalization (data not shown), but co-treatment blocked internalization 
induced by DAMGO (Fig. 3). In contrast, co-treatment with 1 μ M ignavine and 1 μ M DAMGO induced MOR 
internalization 10 min after treatment and vesicle formation was enhanced compared to that with DAMGO alone. 
Taken together, these results suggest that ignavine can modulate MOR activity and that the mode of modulation 
differs depending on its concentration.
Intracellular cAMP assay of ignavine. G protein-coupled receptors activate two directional signaling 
pathways. One is via β -arrestin which leads to induction of receptor internalization; the other is through second 
Figure 1. Rat pharmacokinetic study of GJG and structure of ignavine. (A) A dose of 1 g/kg GJG was orally 
administered and blood samples were collected 1 h after administration. Quantitative analysis of the ingredients 
in PAT was performed using LC/MS/MS. Data are expressed as mean + /− SD (n = 5). (B) Ignavine is a 
diterpene alkaloid and has a different core structure from the aconitine alkaloids.
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messengers such as cAMP and Ca2+. Since MOR belongs to the Gi-coupled family of receptors, activation of 
MOR leads to a decrease in intracellular cAMP level. We next investigated the effect of ignavine on intracellular 
cAMP content. Intracellular cAMP was measured using a biosensor protein, GloSensor™ (Promega, Madison, 
WI, USA). This technology enables kinetic measurement of cAMP18. The experimental design is shown in 
Fig. 4A. Cells were simultaneously treated with ignavine and DAMGO 10 min before stimulation with forskolin, 
then the amount of intracellular cAMP was traced by luminescence intensity. The results showed that DAMGO 
inhibited the increase of intracellular cAMP induced by forskolin (Supplementary Figure S3). Ignavine alone 
showed no effect on intracellular cAMP levels either 7.5 min or 23.5 min after forskolin treatment (Fig. 4B,C). 
However, when added together with 100 nM DAMGO, ignavine showed an intriguing characteristic, with a con-
centration of 1 μ M enhancing the activity of DAMGO in the early period (Fig. 4B) but a concentration of 10 μ M 
inhibiting DAMGO activity in the later period (Fig. 4C). These data are in good accordance with the results of 
the receptor internalization assay. In addition to DAMGO, other MOR agonists and antagonists, endomorphin-1, 
morphine and naloxone were evaluated in this assay. Ignavine also enhanced the activity of these endogenous and 
exogenous agonists 7.5 min after forskolin stimulation (Fig. 4D,E) and inhibited them 23.5 min after stimulation 
(Supplementary Figure S4). On the other hand, ignavine did not show a clear response in the presence of nalox-
one (Fig. 4F and Supplementary Figure S4).
We next investigated whether or not a representative MOR antagonist, naloxone, had similar characteristics 
to ignavine. As shown in Fig. 4G,H, naloxone blocked the activity of DAMGO at both time points. These results 
indicate that ignavine has a unique character different from that of the typical MOR antagonist.
Figure 5 shows the effect of ignavine on the dose titration curve and EC50 values of DAMGO. In agreement 
with the previous results, ignavine produced a leftward shift in response to DAMGO at 7.5 min after forskolin 
treatment (Fig. 5A) and a rightward shift at 23.5 min (Fig. 5B). EC50 values were significantly shifted, with a 
3.8-fold decrease caused by 1 μ M ignavine at 7.5 min and a 3.3-fold increase with 10 μ M ignavine at 23.5 min 
(Fig. 5C).
In vivo analgesia study of ignavine. Analgesic activity of ignavine was investigated by the tail-flick 
(Fig. 6A) and tail-pressure tests in normal mice (Fig. 6B). Intra-peritoneal administration of ignavine inhibited 
pain in both tests. Maximum activity was shown at a dose of 0.1 mg/kg and analgesic activity was attenuated at 
higher doses. These dose-dependent relationships were similar to the results of in vitro assays.
In silico simulation of the interaction between ignavine and the MOR. Finally, we performed 
a computational simulation study to investigate in detail the interaction between ignavine and MOR protein. 
A human MOR homology model was constructed using the crystal structure of mouse MOR19 as a template 
(Supplementary Figure S5). Morphine and β -funaltrexamine (β -FNA) were used for the simulation study as a 
representative MOR agonist and antagonist, respectively, and we constructed docking models of each ligand 
(Fig. 7). The result of docking simulation suggests that ignavine could also bind MOR at the orthosteric binding 
site. As shown in the constructed docking model, all ligands tested here showed a hydrophilic interaction with 
Asp149 in the human MOR. By using these docking models, we conducted computational analysis of MD simu-
lation over 100 nsec. To estimate the effect of each ligand on the MOR structure during MD simulation, we per-
formed Principal Component Analysis (PCA), one of the methods of multivariate analysis used for analyzing the 
Figure 2. Binding affinity of the components of opioid receptors. (A) Inhibition of competitive radioligand 
binding to the human MOR- ([3H]-diprenorphine), DOR- ([3H]-naltorindole), KOR- ([3H]-diprenorphine), 
and NOP- ([3H]-nocicepine) expressing cell lines and rat whole brain ([3H]-naloxone). Concentration of test 
compounds was 10 μ M. Data are represented as mean (n = 2). (B) Concentration-dependent inhibition of 
[3H]-diprenorphine binding against the MOR. Open circles and closed circles represent naloxone and ignavine 
respectively. IC50 values of naloxone and ignavine were 5.1 nM and 2.0 μ M respectively. Data are represented as 
mean + /− SEM (n = 3).
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net effect of phenomena consisting of numerous factors, of the structural coordinate of each MOR–ligand com-
plex. By using the root mean square deviation (RMSD) distance data for Cα atoms of the transmembrane region 
in human MOR models obtained from this computation, each trajectory data-set was plotted in accordance with 
principal components 1 and 2 for abscissa and ordinate, respectively. As shown in Fig. 8A, the three ligands tested 
here could be clearly distinguished in a 2-dimensional scatterplot of PCA. In addition to PCA analysis, a spatial 
fluctuation map, which represents the conformational flexibility during MD simulation, is shown in Fig. 8B. The 
flexibility of the loop structure between TM5 and TM6 in our ignavine-docking model was smaller than those 
in morphine- and β -FNA-docking models. These simulation data suggest that the structural change caused by 
ignavine binding would be different to that caused by either the reference agonist (morphine) or the antagonist 
(β -FNA).
Discussion
In this study, we explored the candidate components which were expected to play a role in analgesic activity of 
PAT. From our data we identified ignavine and found this candidate molecule to affect MOR activity in a unique 
manner and to exert analgesic activity in mice.
A pharmacokinetic study of GJG showed that ignavine and benzoylmesaconine could be detected in the 
plasma 1 hour after administration (Fig. 1A). Benzoylmesaconine is known to transit to the systemic blood cir-
culation after oral administration of either benzoylmesaconine alone or of PAT-containing prescriptions20,21. The 
result shown in this study is in line with previous reports. Although benzoylmesaconine has analgesic activity 
itself15, it does not interact with opioid receptors according to the results of our binding assay (Fig. 2). Therefore, 
Figure 3. Receptor internalization of MOR. MOR-GFP-expressing HEK-293 cells were treated with 
DAMGO and/or ignavine (IGN). DAMGO induced vesicle formation (shown by red arrowheads) in the 
intracellular space, which represented receptor internalization, 20 min after administration. A concentration 
of 10 μ M ignavine blocked internalization. In contrast, 1 μ M ignavine accelerated DAMGO-induced receptor 
internalization.
www.nature.com/scientificreports/
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benzoylmesaconine must act to suppress pain independent of opioid signaling. On the other hand, ignavine 
was detected at the highest concentration among the measured components. This is the first report to show that 
Figure 4. Intracellular cAMP assay. Intracellular cAMP levels were evaluated using the recombinant cell 
line stably expressing the MOR and cAMP biosensor protein. (A) Test compounds (ignavine (IGN), naloxone 
(NLX) + DAMGO, endomorphin-1 (EMP-1), morphine (MRP) or NLX) were added 10 min before forskolin 
(Fsk) treatment. Then, luminescence intensity was measured at 7.5 min (B,D–F,G) and 23.5 min (C,H). 
Ignavine significantly inhibited MOR activation by DAMGO in the late phase (C), but in contrast, enhanced the 
activation of DAMGO in the early phase (B). Ignavine also showed positive modulation of EMP-1 (D) and MRP 
(E), but not NLX (F), at 7.5 min after Fsk stimulation. NLX inhibited MOR activation by DAMGO during both 
phases (D,E). Data are expressed as mean + /− SEM (n = 3–6). * P < 0.05, * * P < 0.01, * * * P < 0.001 by Dunnett’s 
test vs. DMSO - 100 nM DAMGO.
www.nature.com/scientificreports/
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ignavine could be absorbed into the systemic blood. Ignavine is a diterpene alkaloid, with a different structure 
from the aconitine alkaloids, and is a component of Aconitum tuber22 and PAT23. Ignavine has been reported to 
be one of the low-toxicity components of Aconitum tuber and to have anti-inflammatory activity in the acetic 
Figure 5. Dose-response curve in intracellular cAMP assays. (A,B) Activation curves show representative 
data from three independent experiments. In the early phase (7.5 min after forskolin administration), ignavine 
shifted the activation curve of DAMGO to the left, which indicated that ignavine worked as an MOR enhancer 
(A). In contrast, in the late phase (23.5 min after forskolin administration), ignavine shifted the activation curve 
to the right, which indicated that ignavine acted as an MOR inhibitor (B). EC50 values of DAMGO and Ratio 
(fold-change of EC50) are shown in (C). Data shown represent the mean + /− SEM (n = 3). * P < 0.05;  
* * P < 0.01; * * * P < 0.001 by Dunnett’s test vs. DMSO.
Figure 6. Effects of ignavine on antinociception assessed by the tail-flick test (A) and tail-pressure test (B). 
Ignavine (IGN) and morphine (MRP) were intra-peritoneally or subcutaneously administered, respectively. 
Responses to each stimulant were measured at 30, 60, 90, 120 and 180 min after administration. Analgesic 
activity is represented by the area under the curve. Data represent the mean + /− SEM (n = 10–11). * P < 0.05;  
* * P < 0.01; * * * P < 0.001 by Dunnett’s test vs. vehicle. ###P < 0.001 by Student’s t-test vs. vehicle.
www.nature.com/scientificreports/
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acid-induced writhing and carrageenan paw edema test without any adverse effects24. However, no target mol-
ecules of ignavine have been identified to date. In this study, using the receptor binding assay, we found that 
ignavine specifically interacts with MOR.
An in vitro functional assay revealed that ignavine exhibited bidirectional activity in a concentration-dependent 
manner. At high concentrations (> 10 μ M), ignavine inhibited MOR activity both in a receptor internalization 
assay and in an intracellular cAMP assay (Figs 3 and 4). It has been reported that high doses of PAT inhibit the 
antinociception induced by morphine in mice25. The inhibitory activity of ignavine might therefore contribute 
to this phenotype. In contrast, enhancement of MOR activity was observed at low concentrations of ignavine 
(~1 μ M). In the tail-flick test, 0.1 mg/kg ignavine showed the maximum response, while higher concentrations 
of ignavine weakened analgesic activity (Fig. 6A). The tail pressure test also showed the same tendency towards 
dose dependence. These bell-shaped dose-dependency curves observed in vivo were in good accord with the 
in vitro profiles of ignavine. Since ignavine was shown to enhance the activity of the endogenous MOR ligand, 
endomorphin-1 (Fig. 4D), it is possible that it may exert analgesic activity by single administration in vivo. 
Therefore, it can be presumed that the interaction of ignavine with the MOR might be involved in analgesia in 
these mice.
Figure 7. Predicted interactions between ligands and a human MOR homology model viewed from the 
extracellular side (left panel) and parallel to the membrane (right panel). Ignavine (A), morphine (B) and  
β -FNA (C) all have a quaternary amine structure, which interacts with Asp149. This interaction is shown by a 
yellow dotted line.
www.nature.com/scientificreports/
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Ignavine positively modulated the response of DAMGO at a low concentration (~1 μ M). In the present study, 
ignavine accelerated the receptor internalization triggered by DAMGO (Fig. 3) and enhanced the potency of sev-
eral MOR agonists in the intracellular cAMP assay (Fig. 4) without affecting MOR activity when used alone. These 
features are comparable to those of the positive allosteric modulator, BMS-986122, reported by Burford et al.26. 
Although the binding site of BMS-986122 is different from that of ignavine (ignavine binds the MOR orthoster-
ically (see below)), BMS-986122 showed positive modulation of endomorphin-I both in β -arrestin recruitment 
and in intracellular cAMP assay. Since positive modulators of MOR are expected to maintain the temporal and 
spatial fidelity of native signaling, they are proposed to avoid on-target side effects of exogenous MOR agonists 
such as respiratory suppression, constipation, allodynia, tolerance, dependence and withdrawal symptoms27. Our 
results showed that a single administration of ignavine exerted an analgesic effect in mice. Therefore, ignavine is 
also likely to be a promising agent for analgesia. A long-term dosing study should be performed to investigate any 
adverse effects of ignavine.
Regarding the binding site of ignavine, the receptor binding assay showed that ignavine inhibited the binding 
of [3H]-diprenorphine, which has the same structure as morphine and β -FNA. The docking simulation supports 
the result of the binding assay. Like morphine and β -FNA, ignavine has a quaternary amine structure. This struc-
ture has been reported to interact with Asp147 of the rat MOR (Asp149 in the human MOR as shown in Fig. 7) 
and this interaction is important for the pharmacological properties of morphine19,28. Taken together with these 
results, these data strongly suggest that ignavine directly interacts with the MOR at the orthosteric binding site.
Additionally, MD simulation of an ignavine-MOR complex model indicates that orthosteric binding of 
ignavine induces structural change in a unique manner (Fig. 8). PCA analysis of MD simulation clearly distin-
guishes the trajectory of conformation change induced by ignavine from those brought about by a representative 
MOR agonist and antagonist. Since the PC-1 axis divides the three compounds, the difference might reflect the 
unique character of ignavine. On the PC-2 axis, the plot area of ignavine overlapped that of β -FNA and was sep-
arate from that of morphine, indicating that the PC-2 axis might differentiate between agonist and antagonist.
Docking simulation indicates that a single MOR binding pocket does not have enough capacity to accommo-
date both ignavine and an agonist simultaneously. Since opioid receptors including MOR can form homo- and 
hetero-dimers in recombinant-expressing cells29, these dimeric opioid receptors would have two binding pockets. 
The binding assay clearly showed that ignavine is an orthosteric ligand for MOR. Therefore, the excess amount 
of ignavine should occupy both binding pockets in an MOR dimer as suggested in Fig. 2B (high concentrations 
of ignavine completely inhibited the binding of [3H]-diprenorphine). However, if the concentration of ignavine 
was not sufficient, ignavine would not occupy both pockets, leaving one of the pockets vacant. Because the low 
and high concentrations of ignavine increased and decreased the activity of agonists, respectively, we propose the 
following hypothesis: when ignavine and another agonistic ligand (such as DAMGO, morphine, or endogenous 
endomorphin-1) occupy each binding pocket in a homodimer, ignavine might exert positive modulatory activity. 
On the other hand, ignavine at higher concentration would bind to both binding pockets in a homodimer, exert-
ing antagonistic activity. It has been reported that DOR ligands can enhance DAMGO binding capacity in a μ -δ 
heteromer30. It is hypothesized that DOR ligands bind the DOR of the heteromer and “allosterically” modulate 
the activity or binding capacity of the partner receptor. Ignavine is also expected to exert an enhancing effect on 
activity by a similar mechanism. Smith et al. named the allosteric modulation mentioned above as “off-target 
allosterism”, meaning allosteric modulation of another binding site (orthosteric or allosteric) on a distinct protein 
such as a dimeric partner31. Therefore ignavine could be defined as an “off-target allosteric modulator”.
Figure 8. Molecular dynamics simulation of the ignavine–human MOR complex. (A) Two-dimensional 
principal component analysis (PCA) projections of trajectories obtained from MD simulations. (B) Root mean 
square fluctuations (RMSF) of each amino acid residue in the human MOR molecule during MD simulation. 
Data of ignavine, morphine and β -FNA are represented in red, blue and green, respectively.
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Since PAT can produce analgesia directly or indirectly through the KOR and/or induction of dynorphin 
release2,10, it is possible that ignavine might contribute to the analgesic activity of PAT by modulating μ -κ heter-
omer signaling. To test this hypothesis, it will be necessary to evaluate the effect of ignavine on μ -κ heteromer sig-
naling. We plan to carry out the characterization of ignavine’s activity with heteromers including μ -κ heteromer.
In conclusion, we identified ignavine and demonstrated the possibility that ignavine produces analgesia via 
positive modulation of MOR signaling. Pain management using a positive modulator of opioid receptors is an 
attractive approach to avoid the serious adverse effects of conventional opioid drugs. It is expected that ignavine 
could be a candidate compound to evaluate this promising strategy.
Materials
Goshajinkigan, benzoylmesaconine and ignavine were supplied by Tsumura (Tokyo, Japan). DAMGO, naloxone, 
forskoline, 3-isobutyl-1-methylxanthine (IBMX) and Ro 20-1724 were purchased from Sigma Aldrich (St Louis, 
MO, USA). Morphine hydrochloride was purchased from Takeda Pharmaceutical Co., Ltd. (Tokyo, Japan).
Rat pharmacokinetic study. All experimental procedures were ethically approved by the Laboratory 
Animal Committee of Tsumura and Co. and performed according to the institutional guidelines for the care and 
use of laboratory animals, which is in accordance with the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals.
Male Sprague-Dawley rats (7 weeks, Japan Clea Inc., Tokyo, Japan) were fasted for more than 16 hours with 
access to water. At 1 h after oral administration of GJG (1.0 g/10 mL/kg, n = 5), blood samples were collected with 
a heparin-coated syringe and centrifuged at 1,500 × g for 15 minutes at 4 °C. The plasma samples were stored at 
− 80 °C until use.
Plasma samples were pretreated by solid-phase extraction (Oasis® MCX μ Elution Plate, 30 μ m; Waters 
Corporation, Milford, MA, USA) and injected into the LC/MS/MS system for analysis. Components of GJG in 
plasma were measured by a QTRAP® 5500 system (AB SCIEX, Framingham, MA, USA ) equipped with an Agilent 
1260 HPLC system (binary pump, online degasser, auto plate-sampler and column oven; Agilent Technologies, 
Santa Clara, CA, USA). The lower limits for quantification were 0.01 ng/mL for ignavine; 0.002 ng/mL 
for benzoylaconine; 0.001 ng/mL for benzoylmesaconine, benzoylhypaconine and 14-anisoylaconine.
Plasmid constructs and transfection. Human MOR cDNAs (NM_000914) with or without a stop codon 
were amplified from the Flexi ORF clone (Promega, Madison, WI, USA). The amplified human MOR fragment 
was introduced into the pcDNA3.1 (+ ) vector (Life Technologies, Carlsbad, CA, USA). Additionally, the GFP 
coding sequence was inserted into the 3′ terminus of the stop codon-deleted human MOR sequence. Using these 
constructed plasmids, HEK-293 cells stably expressing the human MOR or human MOR-GFP complex were 
generated using Lipofectamine reagent (Life Technologies) and selected by MOR activity. Regarding non-tagged 
human MOR-expressing HEK-293 cells, pGloSensor™ -22F plasmid (Promega) was additionally introduced into 
the cells and stable cell lines were generated.
Binding assay. The receptor binding assay for primary screening was performed by MDS Pharma Services 
(King of Prussia, PA, USA). Assays were performed under the conditions indicated in Table 1. A dose titration 
study was performed using human MOR-expressing HEK-293 cells established in this study. Whole cell fractions 
were incubated with [3H]-diprenorphine (Perkin Elmer, Waltham, MA, USA) in the presence of varying concen-
trations of ignavine or naloxone. After 1 h, assays were harvested onto GF/C filtermats using a Filtermate har-
vester (Perkin Elmer). Then, MeltiLex scintillant (Perkin Elmer) was melted onto dried filtermats and the residual 
bound radioligand was measured by scintillation counting in a TriLux microbeta counter (Perkin Elmer). The 
result of the binding assay was expressed as % inhibition, where % inhibition = 100 × (1− ((CPMtest− CPMnsb)/
(CPMtb− CPMnsb))), CPM: Count per minute, CPMtest: CPM obtained in the presence of test compound, 
CPMnsb: CPM obtained in the presence of non-specific ligand, CPMtb: CPM obtained without cold compound.
Receptor internalization assay. Internalization assay was performed using the HEK-293 cells sta-
bly expressing the human MOR-GFP complex. When the GPCR is activated and internalized, the receptor is 
observed inside vesicle-like structures within the cytoplasm. This phenomenon was evaluated by imaging the 
fluorescence of the GFP-tag, which revealed translocation of the receptor from the plasma membrane to intra-
cellular vesicles. Cells were seeded into a four-compartment cell culture dish at 1.5 × 105 cells/compartment in 
DMEM supplemented with 10% fetal bovine serum. The next day, the culture medium was changed to assay 
buffer (20 mM HEPES, 115 mM NaCl, 5.4 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2 and 13.8 mM D-glucose at 
pH 7.4), and incubation was performed at room temperature. Cells were then treated with ignavine, DAMGO or 
Ligand Kd Bmax Non-specific ligand
MOR Diprenorphine 0.41 nM 3.8 pmol/mg 10 μ M Naloxone
KOR Diprenorphine 0.4 nM 1.1 pmol/mg 10 μ M Naloxone
DOR Naltrindole 0.49 nM 8.6 pmol/mg 10 μ M Naloxone
NOP Nociceptin 1 nM 4.6 pmol/mg 1 μ M Orphanin-FQ
Rat brain Naloxone 1.4 nM 0.095 pmol/mg 1 μ M Naloxone
Table 1.  Assay condition of the receptor binding assay.
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co-treated with ignavine and DAMGO. Fluorescence images of these treated groups were obtained with the same 
timing using a fluorescence microscope BZ-9000 (Keyence, Tokyo, Japan).
Intracellular cAMP assay. The GloSensor™ cAMP biosensor (Promega) uses a modified form of firefly 
luciferase containing a cAMP-binding motif. Upon cAMP binding, a conformational change leads to enzyme 
complementation, and incubation with luciferase substrate then results in a luminescence readout18. Analysis 
of cAMP accumulation was performed in the HEK-293 cells stably expressing Glosensor™ 22F protein and the 
human MOR. The cells were seeded into poly-D-lysine-coated 96-well white, clear-bottomed plates (Corning, 
Corning, NY, USA) at 3 × 104 cells/well in DMEM supplemented with 10% fetal bovine serum. The next day, 
intracellular cAMP assay was performed using the GloSensor™ reagent following the supplied instructions. 
Cells were incubated with diluted GloSensor™ reagent at room temperature for 2 h, then stimulated with a test 
compound (ignavine or naloxone) and DAMGO in assay buffer with 250 μ M IBMX and 50 μ M Ro 20–1724 
for 10 min, followed by the addition of forskolin. Changes in luminescence were detected using FlexStation 3 
(Molecular Devices, Sunnyvale, CA, USA). The baseline level of luminescence was measured before test com-
pound application. The response was expressed as % inhibition, which represented the percentage inhibition 
of forskolin-stimulated cells, or the percentage responses of 3 μ M DAMGO-treated cells in each test compound 
treatment group. Concentration–response curves were fitted using Graph Pad Prism software (Graphpad 
Software, La Jolla, CA, USA) with a Hill equation model.
Mouse nociception test. Antinociceptive responses were evaluated by the tail-flick test (Tail flick unit; Ugo 
Basile, Comerio, Italy) and the tail-pressure test (Pressure analgesimeter; Ugo Basile). The latency (sec) or weight 
(g) at which mice struggled or withdrew was considered the nociceptive threshold. The antinociceptive activities 
were calculated as the area under the time exposure curve (AUC) by plotting the percentage increase in the nocic-
eptive threshold (100 × (post-drug nociceptive threshold/pre-drug nociceptive threshold)− 100) on the ordinate 
and the time interval (min) on the abscissa.
Homology modeling, ligand docking and MD simulation. Homology modeling of the human 
MOR was conducted using the structure of the mouse MOR complex with β -FNA (PDBID: 4DKL) using Prime 
(Schrödinger LLC, New York, NY, USA). The third intracellular loop was truncated by the five residues leading 
out of helix V and the five residues leading into helix VI because it is very long and predicted to be disordered. 
Initial coordinates of ignavine and morphine were derived from the PubChem database. Energy minimization of 
ignavine and morphine were performed by the OPLS-AA force field in the LigPrep in Maestro (Schrödinger LLC). 
These minimized structures were employed as input structures for docking simulations. The human MOR struc-
ture was prepared for docking simulations using the Protein Preparation Wizard Script within Maestro. Docking 
simulations were performed using the Glide SP docking program (Schrödinger LLC). The hydrogen-bonding 
constraint between the side chain COO- group of Asp 149 was introduced because this hydrogen-bonding for-
mation is highly conserved in almost all known complexes of the Class A GPCR family bound to a wide variety of 
agonists or antagonists. All of the docked structures were then ranked according to GlideScore. The best position 
for each docked ligand was manually selected based on both the GlideScore and similarity of the protein–ligand 
interaction fingerprint to the MOR-β -FNA complex.
Ligand-bound model structures of human MOR were subjected to 100 ns MD simulations using Desmond 
version 2.332. The OPLS2005 force field was used for the simulations. Initial model structures were placed into 
a large palmitoyloleoylphosphatidylcholine (POPC) bilayer and TIP3P water molecules solvated with 0.15 M 
NaCl. After minimization and relaxation of the model, the production MD phase was performed for 50 ns in 
the isothermal–isobaric (NPT) ensemble at 300 K and 1 bar using Langevin dynamics. Long-range electrostatic 
interactions were computed using the Smooth Particle Mesh Ewald method. All system setups were performed 
using Maestro.
Principal Component Analysis. Principal component analysis (PCA) was performed on the 3D coordi-
nates of Cα atoms of the transmembrane region in the MOR docking models for MD trajectories. The PCA 
results of three docking structures were analyzed, and the conformational differences were visualized by plotting 
to PC1 (primary component 1) and PC2 axes. PCA is a standard statistical method routinely used to identify 
variable correlations in a system from atomic fluctuations in an MD trajectory. The distance matrix of root mean 
square deviation (RMSD) of the MOR Cα atoms for the combined trajectories of three docking structures was 
calculated for preparation of input matrix to PCA. PCA was performed using R (version 3.1.1.) which is a soft-
ware language and environment for statistical computing and graphics.
Statistical analysis. All values are expressed as means + /− SEM or SD. The statistical significance was 
evaluated by one- or two-way analysis of variance (ANOVA) followed by Dunnett’s test or Student’s t-test. A 
probability of less than 0.05 was considered significant.
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